Literature DB >> 20335217

mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS.

Heth R Turnquist1, Jon Cardinal, Camila Macedo, Brian R Rosborough, Tina L Sumpter, David A Geller, Diana Metes, Angus W Thomson.   

Abstract

Prolonged inhibition of the kinase, mammalian target of rapamycin (mTOR), during myeloid dendritic cell (DC) generation confers resistance to maturation. Recently, however, mTOR inhibition immediately before Toll-like receptor ligation has been found to exert proinflammatory effects on myeloid cells, notably enhanced IL-12p40/p70 production. We show, for the first time, that mouse or human DCs generated under mTOR inhibition exhibit markedly enhanced IL-12p70 production after lipopolysaccharide (LPS) stimulation, despite impaired costimulatory molecule expression and poor T-cell stimulatory ability. Consistent with this finding, we reveal that increased IL-12p40 production occurs predominantly in CD86(lo) immature DCs. High IL-12p40/p70 production by CD86(lo) DC resulted from failed down-regulation of glycogen synthase kinase-3 (GSK-3) activity and could not be ascribed to enhanced Akt function. Despite high IL-12p70 secretion, rapamycin-conditioned, LPS-stimulated DCs remained poor T-cell stimulators, failing to enhance allogeneic Th1 cell responses. We also report that inhibition of GSK-3 impedes the ability of LPS-stimulated DCs to induce forkhead box p3 in CD4(+)CD25(-) T cells, as does the absence of IL-12p40/p70. Thus, GSK-3 activity in DC is regulated via signaling linked to mTOR and modulates their capacity both to produce IL-12p40/p70 and induce forkhead box p3 in CD4(+) T cells under inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335217      PMCID: PMC2890188          DOI: 10.1182/blood-2009-10-251488

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  CD4 T cells: fates, functions, and faults.

Authors:  Jinfang Zhu; William E Paul
Journal:  Blood       Date:  2008-09-01       Impact factor: 22.113

2.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.

Authors:  S Ikeda; S Kishida; H Yamamoto; H Murai; S Koyama; A Kikuchi
Journal:  EMBO J       Date:  1998-03-02       Impact factor: 11.598

3.  IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells.

Authors:  Heth R Turnquist; Tina L Sumpter; Allan Tsung; Alan F Zahorchak; Atsunori Nakao; Gerard J Nau; Foo Y Liew; David A Geller; Angus W Thomson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  IL-12R beta 2 promotes the development of CD4+CD25+ regulatory T cells.

Authors:  Zhao Zhao; Shuo Yu; Denise C Fitzgerald; Mohamed Elbehi; Bogoljub Ciric; A M Rostami; Guang-Xian Zhang
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

5.  Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells.

Authors:  Astrid J van Beelen; Zuzana Zelinkova; Esther W Taanman-Kueter; Femke J Muller; Daniel W Hommes; Sebastian A J Zaat; Martien L Kapsenberg; Esther C de Jong
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745

6.  Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells.

Authors:  Masashi Ohtani; Shigenori Nagai; Shuhei Kondo; Shinta Mizuno; Kozue Nakamura; Masanobu Tanabe; Tsutomu Takeuchi; Satoshi Matsuda; Shigeo Koyasu
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

Review 7.  Defining the role of mTOR in cancer.

Authors:  David A Guertin; David M Sabatini
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

8.  Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner.

Authors:  M Caspi; A Zilberberg; H Eldar-Finkelman; R Rosin-Arbesfeld
Journal:  Oncogene       Date:  2008-01-28       Impact factor: 9.867

Review 9.  Expanding mTOR signaling.

Authors:  Qian Yang; Kun-Liang Guan
Journal:  Cell Res       Date:  2007-08       Impact factor: 25.617

10.  Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.

Authors:  Paolo Monti; Miriam Scirpoli; Paola Maffi; Lorenzo Piemonti; Antonio Secchi; Ezio Bonifacio; Maria-Grazia Roncarolo; Manuela Battaglia
Journal:  Diabetes       Date:  2008-06-16       Impact factor: 9.461

View more
  65 in total

1.  Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1.

Authors:  Jonathan Brown; Huizhi Wang; Jill Suttles; Dana T Graves; Michael Martin
Journal:  J Biol Chem       Date:  2011-11-01       Impact factor: 5.157

2.  IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells.

Authors:  Qianting Yang; Gang Li; Yibei Zhu; Lin Liu; Elizabeth Chen; Hēth Turnquist; Xueguang Zhang; Olivera J Finn; Xinchun Chen; Binfeng Lu
Journal:  Eur J Immunol       Date:  2011-10-13       Impact factor: 5.532

3.  mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo.

Authors:  Dàlia Raïch-Regué; Brian R Rosborough; Alicia R Watson; Mandy J McGeachy; Hēth R Turnquist; Angus W Thomson
Journal:  J Immunol       Date:  2015-04-03       Impact factor: 5.422

4.  Cutting edge: Flt3 ligand mediates STAT3-independent expansion but STAT3-dependent activation of myeloid-derived suppressor cells.

Authors:  Brian R Rosborough; Lisa R Mathews; Benjamin M Matta; Quan Liu; Dàlia Raïch-Regué; Angus W Thomson; Hēth R Turnquist
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

5.  IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival.

Authors:  Heth R Turnquist; Zhenlin Zhao; Brian R Rosborough; Quan Liu; Antonino Castellaneta; Kumiko Isse; Zhiliang Wang; Megan Lang; Donna Beer Stolz; Xin Xiao Zheng; A Jake Demetris; Foo Y Liew; Kathryn J Wood; Angus W Thomson
Journal:  J Immunol       Date:  2011-09-26       Impact factor: 5.422

6.  Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells.

Authors:  B Mfarrej; T Jofra; C Morsiani; N Gagliani; G Fousteri; M Battaglia
Journal:  Clin Exp Immunol       Date:  2020-05-13       Impact factor: 4.330

7.  Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells.

Authors:  Yanyan Wang; Gonghua Huang; Hu Zeng; Kai Yang; Richard F Lamb; Hongbo Chi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

Review 8.  Regulatory myeloid cells in transplantation.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Heth R Turnquist; Angus W Thomson
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

9.  Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Benjamin M Matta; Keunwook Lee; Boyi Gan; Ronald A DePinho; Holger Hackstein; Mark Boothby; Hēth R Turnquist; Angus W Thomson
Journal:  Blood       Date:  2013-02-26       Impact factor: 22.113

10.  p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin.

Authors:  Karl Katholnig; Christopher C Kaltenecker; Hiroko Hayakawa; Margit Rosner; Caroline Lassnig; Gerhard J Zlabinger; Matthias Gaestel; Mathias Müller; Markus Hengstschläger; Walter H Hörl; Jin Mo Park; Marcus D Säemann; Thomas Weichhart
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.